Probius

Quantum electrochemical sensing for reagent-free diagnostics

Website: https://www.probius.bio/

PUBLIC
Name Probius
Tagline Quantum electrochemical sensing for reagent-free diagnostics
Headquarters Fremont, California, United States
Founded 2016
Stage Seed
Business Model B2B
Industry Deeptech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label Undisclosed
Total Disclosed $12.9M (estimated) [PitchBook, 2026]

Links

PUBLIC

Executive Summary

PUBLIC Probius is a deep-tech biotech company developing a reagent-free diagnostic platform, a proposition that warrants investor attention due to its potential to address critical bottlenecks in global health diagnostics and its recent validation through a Gates Foundation grant [Parsers VC, Jan 2026]. Founded in 2016 in Fremont, California, the company has spent nearly a decade in R&D to build its quantum electrochemical sensing (QES) technology, which aims to identify molecules and single-cell organisms in raw samples without preparation [Perplexity Sonar Pro, Jan 2026]. The core product is a point-of-care diagnostic, initially targeting tuberculosis with a claimed 30-minute AI-powered screener designed for resource-limited settings [Perplexity Sonar Pro, Jan 2026].

The founding team brings specialized technical expertise: CEO Emmanuel P. Quevy has a background in advanced sensors and MEMS engineering from roles at Silicon Laboratories and Silicon Clocks, while CTO Chaitanya Gupta has academic and industry experience in life sciences, with affiliations to Stanford University [The Org, 2026] [ResearchGate, 2026]. Capitalization is not publicly detailed, but the company is reported to have raised over $15 million from a mix of Department of Defense sources and early-stage investors like UCeed and Zoic Capital, and it participated in the Plug and Play Tech Center accelerator [Perplexity Sonar Pro, Jan 2026] [Crunchbase, 2026]. Over the next 12-18 months, the key milestones to watch are the technical and clinical validation of the TB diagnostic platform under the Gates Foundation grant and the company's ability to transition from deep-tech R&D to a commercializable product with defined regulatory and go-to-market pathways. Data Accuracy: YELLOW -- Key claims (grant, technology, team background) are cited but rely on limited or single-source corroboration; financial figures are estimated.

Taxonomy Snapshot

Axis Classification
Stage Seed
Business Model B2B
Industry / Vertical Biotech / Life Sciences
Technology Type Deeptech
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)

Company Overview

PUBLIC

Probius is a deep-tech biotech company that began its development path in 2016, based in Fremont, California [Crunchbase, 2026]. The company operates as ProbiusDx Inc., focusing on the development of a quantum electrochemical sensing platform for diagnostics [ResearchGate, 2026]. Its founding narrative centers on applying over a decade of research in sensor technology and biochemistry to create reagent-free diagnostic tools, a proposition that recently garnered a grant from the Gates Foundation for tuberculosis screening [Parsers VC, Jan 2026].

Key operational milestones have been technical and grant-based rather than commercial. The company emerged from stealth with a public announcement in September 2022, highlighting the addition of executive team members in scientific and business development roles [BusinessWire, Sep 2022]. This was followed by the January 2026 Gates Foundation grant, which represents the most significant public validation of its technology's application to date [Parsers VC, Jan 2026]. The company's headcount is reported in a range between 11 and 50 employees [Perplexity Sonar Pro, Jan 2026].

Data Accuracy: YELLOW -- Core facts (founding year, location, grant) are corroborated; employee count and specific entity details rely on single or inferred sources.

Product and Technology

MIXED

Probius is building a diagnostic platform that aims to eliminate the sample preparation steps that dominate time and cost in traditional lab work. The core of its approach is a proprietary quantum electrochemical sensing (QES) technology, which the company claims can directly identify and quantify a wide range of biological targets,from small molecules to single-cell organisms,in raw, unprocessed samples [Perplexity Sonar Pro, Jan 2026]. This reagent-free method is intended to enable rapid, decentralized testing, with a specific application in development being a 30-minute, AI-powered tuberculosis screener for point-of-care use [Perplexity Sonar Pro, Jan 2026]. The platform's value proposition hinges on generating what the company describes as a "high-fidelity digital biochemistry representation," potentially offering orders of magnitude more data than conventional assays.

The technical architecture appears to integrate advanced sensor hardware with machine learning software. Job postings for roles like Sensor Test & Characterization Engineer and Product Test Engineer [Lever.co, 2026] suggest a deep focus on the physics and engineering of the sensing interface, likely involving micro-electromechanical systems (MEMS) given co-founder Emmanuel Quevy's background [The Org, 2026]. The AI component is presumably tasked with interpreting the complex electrochemical signals to deliver specific diagnostic results. A recent grant from the Gates Foundation, announced in January 2026, provides a concrete, publicly validated use case for the technology in global health diagnostics [Parsers VC, Jan 2026].

While the company's website and grant announcement frame the product's potential, detailed specifications on form factor, throughput, or regulatory status are not publicly available. The technology remains in a development phase, as indicated by the hiring focus on test and characterization engineering rather than commercial roles like sales or manufacturing.

Data Accuracy: YELLOW -- Product claims are sourced from a third-party analyst brief and a grant announcement; core technology details are not independently verified by primary technical publications.

Market Research

PUBLIC The market for rapid, decentralized diagnostics is being reshaped by a push for healthcare accessibility and the limitations of traditional laboratory methods, creating a clear opening for novel sensing platforms.

Quantifying the total addressable market for point-of-care diagnostics is complex, with segments spanning infectious disease, chronic condition monitoring, and environmental testing. While Probius has not publicly cited specific TAM figures, the broader context is instructive. The global point-of-care diagnostics market was valued at approximately $40 billion in 2022 and is projected to grow at a compound annual rate of around 8% [Precedence Research, 2023]. Within this, the infectious disease testing segment, which includes tuberculosis screening, represents a significant portion. The tuberculosis diagnostics market alone is estimated at over $2.5 billion [Global Market Insights, 2023]. These figures represent analogous markets for a reagent-free, rapid diagnostic platform like Probius's QES technology.

Demand is driven by several converging tailwinds. The COVID-19 pandemic accelerated the adoption of decentralized testing and exposed vulnerabilities in centralized lab supply chains. There is also a persistent, unmet need for diagnostic tools in low-resource settings where infrastructure is limited and sample transport is impractical. Global health initiatives, such as the World Health Organization's goal to end the TB epidemic, create specific funding and procurement pathways for novel technologies [WHO, 2023]. The Gates Foundation grant awarded to Probius in January 2026 is a direct signal of this demand driver in action [Parsers VC, Jan 2026].

Adjacent and substitute markets provide both opportunity and competitive pressure. Traditional methods like culture-based testing, PCR, and lateral flow assays dominate but have trade-offs in time, cost, and complexity. Emerging competitors are exploring other novel sensing modalities, including CRISPR-based diagnostics and advanced spectroscopy. The key adjacent market for Probius's underlying sensing technology may be in life sciences research, where the ability to perform label-free, multi-analyte detection on raw samples could be valuable for drug discovery and basic science, potentially offering a nearer-term commercialization path.

Regulatory and macro forces present both a hurdle and a potential moat. Any diagnostic intended for clinical use must navigate FDA or equivalent regulatory approval, a process that requires substantial clinical validation and capital. However, a successful clearance creates a significant barrier to entry. Macro trends favoring preventative and personalized medicine support the long-term vision of continuous, multi-parameter health monitoring, though that application horizon is likely a decade away.

Global POC Diagnostics Market (2022) | 40 | $B
TB Diagnostics Market | 2.5 | $B

The chart illustrates the substantial scale of the broader diagnostic markets Probius is entering. The $2.5 billion TB segment represents a clear initial beachhead, validated by the recent Gates Foundation grant, while the larger $40 billion POC market outlines the long-term expansion opportunity.

Data Accuracy: YELLOW -- Market sizing figures are from third-party reports for analogous sectors, not company-specific TAM. The Gates Foundation grant is a confirmed, specific demand signal.

Competitive Landscape

MIXED

Probius positions itself as a deep-tech challenger in the diagnostics space, aiming to bypass traditional sample preparation with a novel quantum electrochemical sensing platform. This places it against both established diagnostic giants and a newer wave of startups seeking to miniaturize and accelerate lab-grade analysis.

If the structured facts include at least one named competitor, render a markdown comparison table. The structured facts list one competitor: SaponiQx. Therefore, a table with at least two rows (Probius and SaponiQx) is required. I need to populate the table columns: Company, Positioning, Stage / Funding, Notable Differentiator, Source.

For Probius:

  • Company: Probius
  • Positioning: From structured facts: "Quantum electrochemical sensing for reagent-free diagnostics." From snippets: "QES platform identifies molecules and single-cell organisms in raw samples without preparation" and "30-minute AI-powered TB screener for point-of-care." I'll synthesize: Quantum electrochemical sensing (QES) for reagent-free, point-of-care diagnostics.
  • Stage / Funding: From structured facts: Stage: Seed. Funding: "Raised $12.9M" [PitchBook, 2026] and "> $15M from DoD and early investors" [Perplexity Sonar Pro, Jan 2026]. I'll use: Seed; $12.9M+ raised (estimated).
  • Notable Differentiator: From snippets: "identifies/quantifies... in raw samples without preparation." Key is reagent-free, no sample prep.
  • Source: For Positioning and Differentiator, cite [Perplexity Sonar Pro, Jan 2026]. For Stage/Funding, cite [PitchBook, 2026] and [Perplexity Sonar Pro, Jan 2026].

For SaponiQx:

  • Company: SaponiQx (only name given, no other details in structured facts). I must not fabricate. I can only use what's in structured facts or snippets. Since no details are provided, I need to write "Not publicly available" for the other columns. But the rule says: "Never emit a table row that contains 'Not publicly available' in every column." This row would have only the Company column filled. However, the spec says: "If there are zero named competitors in the structured facts, OMIT the table entirely." Here we have one named competitor, so a table is required. I'll populate with "Not publicly available" for the other columns, but that would be three columns of NPA. The rule says avoid that, but it's the only option given the data. I'll use it sparingly. Alternatively, I could omit the table if I judge that having only one competitor with no data is insufficient. The spec says: "If the structured facts include at least one named competitor, render a markdown comparison table." It doesn't specify a minimum of data points. I'll render the table with available data.

I'll also consider if any other competitors are implied in the market analysis, but the structured facts only list SaponiQx. I should not introduce new competitor names.

After the table, write 3-4 paragraphs covering the four points.

  1. Segment-by-segment competitive map: Incumbents (large diagnostic companies like Roche, Abbott, Siemens Healthineers) selling centralized lab equipment and assays. Challengers (startups like SaponiQx, other point-of-care diagnostic startups) working on novel sensing technologies. Adjacent substitutes (traditional PCR, lateral flow assays, microscopy).
  2. Defensible edge today: Probius's edge is its proprietary QES technology enabling reagent-free, no-prep analysis. Durability depends on patents and continued R&D. Also, early grant funding (Gates Foundation) for TB could provide a niche foothold.
  3. Exposure: Probius is exposed to competitors with faster commercialization, deeper clinical validation, or stronger distribution channels. Specifically, large incumbents could replicate the technology or acquire other startups. Also, regulatory hurdles for novel diagnostics are high.
  4. 18-month scenario: Winner if Probius secures regulatory clearance for its TB test and partners with a global health organization. Loser if development delays allow competitors with simpler, cheaper technologies to capture the point-of-care market.

Label MIXED at the start. End with Data Accuracy Score line.

Data Accuracy: For this section, the accuracy of competitive info is mixed. Probius data is from public sources (YELLOW/ORANGE). SaponiQx data is not available (RED). Overall, I'll use YELLOW because we have some corroboration for Probius but little for competitors.

Now, write the markdown.

First, the heading. Then MIXED label. Then framing sentence. Then table. Then paragraphs. Then accuracy score.

Ensure no em dashes, banned words, etc.

Paragraph rhythm: short paragraphs.

Citations: every claim cited.

Now, construct the JSON.

Opportunity

PUBLIC

If Probius can commercialize its quantum electrochemical sensing platform, the prize is a foundational shift in decentralized diagnostics, moving complex molecular analysis from centralized labs to any point of care.

The headline opportunity is the creation of a category-defining platform for reagent-free, sample-to-answer diagnostics. The company's core technical claim, that its QES platform can identify molecules and organisms in raw samples without preparation [Perplexity Sonar Pro, Jan 2026], directly targets the primary bottlenecks in global health and personalized medicine: cost, time, and infrastructure. The recent Gates Foundation grant for a 30-minute tuberculosis screener [Parsers VC, Jan 2026] is a specific, high-stakes validation of this wedge. Success here would not merely be a new TB test, it would demonstrate a generalizable platform capable of being reconfigured for other pathogens or biomarkers, establishing Probius as the default infrastructure for rapid, low-resource diagnostics.

The path from a single grant to massive scale hinges on a few concrete scenarios. Each represents a plausible, high-impact expansion of the initial beachhead.

Scenario What happens Catalyst Why it's plausible
Global Health Standard The TB diagnostic achieves WHO prequalification and becomes the standard for active case-finding in high-burden countries. Successful completion and field validation of the Gates Foundation-funded project. The grant explicitly targets a point-of-care solution for resource-limited settings, aligning with a massive, unmet need [Parsers VC, Jan 2026].
Platform Expansion in Biopharma The QES technology is adopted by pharmaceutical companies for rapid, label-free drug candidate screening and biomarker discovery. A partnership with a top-20 pharma company for R&D use. The platform's claimed ability to quantify molecular interactions in raw samples addresses a key pain point in high-throughput screening [Perplexity Sonar Pro, Jan 2026].
Defense & Biosecurity Deployment The sensor is integrated into portable systems for field detection of biological threats. A follow-on contract from the Department of Defense, building on prior R&D funding. The company's technology development has been supported by over $15M from the DoD and early investors, indicating established interest in this application area [Perplexity Sonar Pro, Jan 2026].

Compounding for Probius would manifest as a data and design flywheel. Each new diagnostic assay developed on the QES platform would generate proprietary datasets on molecular-electrochemical signatures. This data could train more accurate AI models for the platform, improving sensitivity and specificity for future assays and creating a data moat that is difficult for new entrants to replicate. Furthermore, a successful flagship product like the TB test would build credibility and a distribution footprint within global health networks, lowering the cost of commercializing subsequent tests for other diseases. Early hiring for sensor characterization and test engineering roles suggests the company is building the operational muscle to iterate on this core technology [Lever.co, 2026].

Quantifying the size of the win requires looking at comparable exits and valuations in the diagnostics and life sciences tools sector. For a scenario where Probius becomes a commercial platform in global health and biopharma research, a relevant benchmark is the 2021 acquisition of Mesa Biotech, a point-of-care molecular diagnostics company, for approximately $450 million in cash plus up to $100 million in milestones. A platform with broader applicability than a single test menu could command a higher multiple. If the "Platform Expansion in Biopharma" scenario gains traction, the company could approach the valuation range of public tools companies like Quanterix (market cap ~$700M as of early 2026), which commercialized a high-sensitivity biomarker detection platform. It is critical to note this is a scenario-based comparable, not a forecast; the vast majority of the value is contingent on technical validation and initial commercial adoption.

Data Accuracy: YELLOW -- Key opportunity claims (platform capability, grant) are from a single secondary source; DoD funding and employee count are partially corroborated but with conflicting figures.

Sources

PUBLIC

  1. [BusinessWire, Sep 2022] Probius Emerges to Transform Data Acquisition for AI in Healthcare | https://www.businesswire.com/news/home/20220914005190/en/Probius-Emerges-to-Transform-Data-Acquisition-for-AI-inHealthcare-adding-John-Baldoni-Chief-Scientific-Officer-and-Juan-C.-Cuevas-SVP-Marketing-and-Business-Development

  2. [Crunchbase, 2026] Probius - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/probius

  3. [Global Market Insights, 2023] Tuberculosis Diagnostics Market Size | https://www.gminsights.com/industry-analysis/tuberculosis-diagnostics-market

  4. [Lever.co, 2026] Probius jobs | https://jobs.lever.co/ProbiusDx

  5. [Parsers VC, Jan 2026] Probius receives Gates Foundation grant for TB diagnostic | https://www.parsers.vc/announcements/probius-gates-grant

  6. [Perplexity Sonar Pro, Jan 2026] Probius Company Brief | https://www.perplexity.ai/search/probius-company-brief

  7. [PitchBook, 2026] Probius 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/229948-03

  8. [Precedence Research, 2023] Point of Care Diagnostics Market Size | https://www.precedenceresearch.com/point-of-care-diagnostics-market

  9. [ResearchGate, 2026] Chaitanya GUPTA | Stanford University, Stanford | https://www.researchgate.net/profile/Chaitanya-Gupta

  10. [The Org, 2026] Emmanuel Quevy Professional Profile | https://theorg.com/org/probius/org-chart/emmanuel-quevy

  11. [WHO, 2023] WHO Global Tuberculosis Programme | https://www.who.int/teams/global-tuberculosis-programme

Articles about Probius

View on Startuply.vc